Русский
Relationship between immunological parameters and the severity of liver fibrosis in patients with chronic hepatitis C
DOI: https://dx.doi.org/10.18565/epidem.2023.13.1.78-82
Ponezheva Zh.B., Akimkin V.G., Mannanova I.V., Ugleva S.V., Duganova S.E., Shabalina S.V.
1) Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; 2) Clinical Infectious Diseases Hospital Two, Moscow, Russia
Subjects and methods. Examinations were made in 69 men and 48 women (mean age 45.7 ± 2.1 years) with a confirmed diagnosis of CHC. The number and functional activity of T lymphocyte subpopulations were studied by flow cytofluorometry using an EPICS XL cytometer (Beckman Coulter, USA). The serum concentration of interferons (IFN-α, IFN-γ, and IFN-λ) was estimated by an enzyme-linked immunosorbent assay (ELISA). Liver fibroelastometry was performed using a Fibroscan 502 device (Echosens, France), whereas the stage of fibrosis was determined using the METAVIR scoring system.
Results. An increase in the total number of T lymphocytes and T helper cells was detected in patients with CHC at all stages of LF. A significant decrease was found in B lymphocytes in patients with fibrosis stages F3 and F4. There was a tendency of IFN-α to decrease and IFN-λ to increase with progression of fibrosis stage.
Conclusion. The findings not only confirm the opinion about the pronounced immunosuppressive effect of viral hepatitis C, but also emphasize the importance of T cell immunity and IFN-γ in the prognosis of severe LF.
Literature
1. Акимкин В.Г., Семененко Т.А., Никитина Г.Ю., Годков М.А., Скворцов С.В. Эпидемиология гепатитов B и C в лечебно-профилактических учреждениях М.: Издательский дом «Бионика», 2013. 216 с. Akimkin V.G., Semenenko T.A., Nikitina G.Yu., Godkov M.A., Skvortsov S.V. [Epidemiology of hepatitis B and C in medical institutions]. Moscow: Publishing house «Bionika», 2013. 216 p. 2. Михайлов М.И., Кюрегян К.К., Малинникова Е.Ю., Исаева О.В., Карлсен А.А.и др. Вирусные гепатиты: прогнозы и проблемы. Эпидемиол. инфекц. болезни. Актуал. вопр. 2019; 9(1): 71–80. DOI: https://dx.doi.org/10.18565/epidem.2019.9.1.71-80 Mikhailov M.I., Kyuregyan K.K., Malinnikova E. Yu., Isaeva О.V., Karlsen A.A. et al. [Viral hepatitis: forecasts and problems]. Epidemiоlоgy and infectious diseases. Сurrent items 2019; 9(1): 71–80. (In Russ.). DOI: https://dx.doi.org/10.18565/epidem.2019.9.1.71-80 3. Понежева Ж.Б., Маннанова И.В., Макашова В.В., Еровиченков А.А., Шабалина С.В., Горелов А.А. Клинико-лабораторная характеристика больных хроническим гепатитом С с выраженной депрессией интерферонового статуса. Инфекционные болезни 2021; 19(2): 60–4. DOI: 10.20953/1729-9225-2021-2-60-64 Ponezheva Zh.B., Mannanova I.V., Makashova V.V., Erovichenkov A.A., Shabalina S.V., Gorelov A.A. [Clinical and laboratory characteristics of patients with chronic hepatitis C with severe depression of interferon status]. Infectious Diseases 2021; 19(2): 60–4. (In Russ.). DOI: 10.20953/1729-9225-2021-2-60-64 4. Report of the WISH Viral Hepatitis Forum 2018 https://burnet.edu. au/system/asset/file/3306/Report_of_the_WISH_Viral_Hepatitis_Forum_2018.pdf 5. WHO Global hepatitis report, 2017. Адрес сайта https://www.who. int/publications-detail-redirect/9789241565455 6. Грушко И.П., Романова Е.Б., Твердохлебова Т.И. Роль эндотелиальной дисфункции в патогенезе хронического гепатита С и способы ее коррекции. Эпидемиол. инфекц. болезни. Актуал. вопр. 2020; 10(2): 56–61. DOI: https://dx.doi.org/10.18565/epidem.2020.10.2.56-61 Grushko I.P., Romanova E.B., Tverdokhlebova T.I. [The role of endothelial dysfunction in the pathogenesis of chronic hepatitis C and methods for its correction]. Epidemiоlоgy and infectious diseases. Сurrent items 2020; 10(2): 56–61. (In Russ.). DOI: https://dx.doi.org/10.18565/ epidem.2020.10.2.56-61 7. Майер К. Гепатит и последствия гепатита. Пер. с нем. М.: ГЭОТАР-Медиа, 2004. 720 с. Mayer K. Hepatitis and the consequences of hepatitis. Translate from German. Moscow: GEOTAR-Media, 2004. 720 p. (In Russ.). 8. Wynn T.A. Common and unigue mechanisms regulate fibrosis in various fibroproliferative diseases. J. Clin. Jnvest. 2007; 117(3): 524–29. 9. Сюткин В.Е. Стратегия лечения больных ХГС на современном этапе. Клиническая фармакология и терапия 2008; (2): 16–8. Syutkin V.E. [The strategy of treatment of patients with CHC at the present stage]. Clinical pharmacology and therapy 2008; (2): 16–8. (In Russ.). 10. Ющук Н.Д., Ивашкин В.Т., Климова Е.А., Маевская М.В., Знойко О.О., Шестакова И.В. и др. Рекомендации по диагностике и лечению взрослых больных гепатитом С. 3-е изд., испр. и доп. М.; ГЭОТАР-Медиа, 2017. 96 с. Yushchuk N.D., Ivashkin V.T., Klimova E.A., Maevskaya M.V.. Znojko O.O., Pavlov Ch.S., Shestakova I.V. et al. [Recommendations for the diagnosis and treatment of adult patients with hepatitis C]. 3rd ed., correct and additional. Moscow: GEOTAR-Media, 2017. 96 p. (In Russ.).
About the Autors
Zhanna B. Ponezheva, MD, Head, Clinical Infectious Pathology Department, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; doktorim@mail.ru; https://orcid.org/0000-0002-6539-4878
Professor Vasily G. Akimkin, Academician of the Russian Academy of Sciences, MD, Director, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; vgakimkin@yandex.ru; https://orcid.org/0000-0003-4228-9044
Irina V. Mannanova, Can. Med. Sci., Researcher, Clinical Infectious Pathology Department, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; irinasemenova07@rambler.ru
Svetlana V. Ugleva, MD, Associate Professor, Advisor, Organization and Guidance Department, Administrative Subdivision, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; uglevasv@rambler.ru; https://orcid.org/0000-0002-1322-0155
Svetlana E. Duganova, MD, Infectiologist, Department Four, Clinical Infectious Diseases Hospital Two, Moscow City Healthcare Department, Moscow, Russia; Svetlana- msk@rambler.ru
Professor Svetlana V. Shabalina, MD, Leading Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; svs2810@pcr.ru
Similar Articles
